European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: The SHARE initiative

Annals of the Rheumatic Diseases

Volumn 76, Issue 11, 2017, Pages 1788-1796

  Groot, Noortje ^a,b,o   De Graeff, Nienke ^a   Avcin, Tadej ^c   Bader Meunier, Brigitte ^d   Brogan, Paul ^e   Dolezalova, Pavla ^f   Feldman, Brian ^g   Kone Paut, Isabelle ^h   Lahdenne, Pekka ⁱ   Marks, Stephen D ^e   McCann, Liza ^j   Ozen, Seza ^k   Pilkington, Clarissa ^e   Ravelli, Angelo ^l   Royen Kerkhof, Annet Van ^a   Uziel, Yosef ^m   Vastert, Bas ^a   Wulffraat, Nico ^a   Kamphuis, Sylvia ^b   Beresford, Michael W ^j,n  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f CHARLES UNIVERSITY   (Czech Republic)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h BICÊTRE HOSPITAL   (France)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^k HACETTEPE UNIVERSITY   (Turkey)

^l UNIVERSITY OF GENOA   (Italy)

^m TEL AVIV UNIVERSITY   (Israel)

ⁿ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^o UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Autoantibodies; Corticosteroids; Disease Activity; Systemic Lupus Erythematosus; Treatment

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB;

ARTICLE; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE CLASSIFICATION; EUROPE; EVIDENCE BASED PRACTICE; HUMAN; IMMUNOASSAY; MACROPHAGE ACTIVATION SYNDROME; NEPHROLOGY; NEUROPSYCHIATRY; ONSET AGE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; RHEUMATOLOGIST; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; CHILD; EVIDENCE BASED MEDICINE; INTERNATIONAL COOPERATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINE; STANDARDS; YOUNG ADULT;

ADOLESCENT; AGE OF ONSET; CHILD; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONAL COOPERATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 85024861932     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210960     Document Type: Article

References (127)

1. Bandeira M, Buratti S, Bartoli M, et al. Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006;15:515-20.
2. Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008;58:556-62.
3. Hersh AO, von Scheven E, Yazdany J, et al. Differences in long-Term disease activity and treatment of adult patients with childhood-And adult-onset systemic lupus erythematosus. Arthritis Rheum 2009;61:13-20.
4. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: A meta-Analysis. Lupus 2011;20:1345-55.
5. Ramírez Gómez LA, Uribe Uribe O, Osio Uribe O, et al. Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 2008;17:596-604.
6. Sag E, Tartaglione A, Batu ED, et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: A multicentre study. Clin Exp Rheumatol 2014;32:440-4.
7. Fonseca AR, Gaspar-Elsas MI, Land MG, et al. Comparison between three systems of classification criteria in juvenile systemic lupus erythematous. Rheumatology 2015;54:241-7.
8. Mina R, Brunner HI. Pediatric lupus-Are there differences in presentation Response to therapy, and damage accrual compared with adult lupus? rheumatic diseases clinics of North America. Genetics 2010;36:53-80. vii-viii.
9. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum 2012;64:2669-76.
10. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
11. Pineles D, Valente A, Warren B, et al. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus 2011;20:1187-92.
12. Huemer C, Huemer M, Dorner T, et al. Incidence of pediatric rheumatic diseases in a regional population in Austria. J Rheumatol 2001;28:2116-9.
13. Kaipiainen-Seppänen O, Savolainen A. Incidence of chronic juvenile rheumatic diseases in Finland during 1980-1990. Clin Exp Rheumatol 1996;14:441-4.
14. López P, Mozo L, Gutiérrez C, et al. Epidemiology of systemic lupus erythematosus in a northern spanish population: gender and age influence on immunological features. Lupus 2003;12:860-5.
15. Nightingale AL, Farmer RD, de Vries CS. Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006;15:656-61.
16. Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic connective tissue diseases in children: A nationwide prospective study in Finland. J Rheumatol 1994;21:2143-6.
17. Series OR. List of rare diseases and synonyms listed in alphabetical order: orphanet, 2016. Available from. http://www. orpha. net/orphacom/cahiers/docs/GB/List- of- rare- diseases- in- alphabetical- order. pdf. (cited 2016 20-01-2017).
18. Wulffraat NM, Vastert B, consortium S; SHARE consortium. Time to share. Pediatr Rheumatol Online J 2013;11:5.
19. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017;76:329-40.
20. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial mediterranean fever. Ann Rheum Dis 2015;74:635-41.
21. ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636-44.
22. Dougados M, Betteridge N, Burmester GR, et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
23. Leclercq E, Leeflang MM, van Dalen EC, et al. Validation of search filters for identifying pediatric studies in PubMed. J Pediatr 2013;162:629-34.
24. T.C Hjptgs. Cochrane Handbook for Systematic Reviews of Interventions, 2013.
25. Whiting P, Rutjes AW, Dinnes J, et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8:iii, 1-234.
26. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. part I: diagnosis. Report of a task force of the standing Committee for International clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
27. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing Committee for International clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
28. vdVA DAL. A group process model for problem identification and program planning. J Appl Behav Sci 1971;7:466-92.
29. Tarr T, Dérfalvi B, Gyóri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus 2015;24:796-803.
30. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 19971725;40:1725.
31. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for Systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
32. Abdwani R, Rizvi SG, El-Nour I. Childhood systemic lupus erythematosus in Sultanate of Oman: demographics and clinical analysis. Lupus 2008;17:683-6.
33. Bader-Meunier BBM AJ, Haddad E, Cochat P, et al. Initial presentation of childhoodonset systemic lupus erythematosus: A French multicenter study. 2005. J pediatr 2005:146.
34. Buoncompagni A, Barbano GC, Pistoia V, et al. Childhood systemic lupus erythematosus: A review of 30 cases. Clin Exp Rheumatol 1991;9:425-30.
35. Chiang LL, Lin YT, Chan HY, et al. Differential manifestations of prepubescent, pubescent and postpubescent pediatric patients with systemic lupus erythematosus: A retrospective study of 96 chinese children and adolescents. Pediatr Rheumatol Online J 2012;10:12.
36. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-Term outcome of pediatric systemic lupus erythematosus: A longitudinal study. J Pediatr 2008;152:550-6.
37. Olowu W. Childhood-onset systemic lupus erythematosus. J Natl Med Assoc 2007;99:777-84.
38. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset systemic lupus Erythematosus Cohort. Arthritis Rheum 2012;64:2356-65.
39. Campos LM, Kiss MH, Scheinberg MA, et al. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus 2006;15:496-500.
40. Hinze CH, Suzuki M, Klein-Gitelman M, et al. Neutrophil gelatinase-Associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum 2009;60:2772-81.
41. Jesus AA, Campos LM, Liphaus BL, et al. Anti-C1q, anti-chromatin/nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients. Rev Bras Reumatol 2012;52:976-81.
42. Jesus AA, Silva CA, Carneiro-Sampaio M, et al. Anti-C1q antibodies in juvenile-onset systemic lupus erythematosus. Ann N Y Acad Sci 2009;1173:235-8.
43. Jurencák R, Fritzler M, Tyrrell P, et al. Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol 2009;36:416-21.
44. Lehman TJ, Hanson V, Singsen BH, et al. The role of antibodies directed against double-stranded DNA in the manifestations of systemic lupus erythematosus in childhood. J Pediatr 1980;96:657-61.
45. Tang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: A retrospective review of 917 patients in South China. Medicine 2010;89:62-7.
46. Wu FQ, Zhao Q, Cui XD, et al. C1q and anti-C1q antibody levels are correlated with disease severity in chinese pediatric systemic lupus erythematosus. Rheumatol Int 2011;31:501-5.
47. Wu JF, Yang YH, Wang LC, et al. Antinucleosome antibodies correlate with the disease severity in children with systemic lupus erythematosus. J Autoimmun 2006;27:119-24.
48. Al-Mayouf SM, Abanomi H, Eldali A. Impact of C1q deficiency on the severity and outcome of childhood systemic lupus erythematosus. Int J Rheum Dis 2011;14:81-5.
49. Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.
50. Crow YJ. Lupus: how much "complexity" is really (just) genetic heterogeneity? Arthritis Rheum 2011;63:3661-4.
51. Bader-Meunier B, Cavé H, Jeremiah N, et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum 2013;43:217-9.
52. Ahmed AM E-SM. Asymptomatic cardiac involvement in children with systemic lupus erythematosus. J Med Sci 2006;6:944-9.
53. Al-Abbad AJ, Cabral DA, Sanatani S, Sandor GGS, et al. Echocardiography and pulmonary function testing in childhood onset systemic lupus erythematosus. Lupus 2001;10:32-7.
54. Cerveri I, Fanfulla F, Ravelli A, et al. Pulmonary function in children with systemic lupus erythematosus. Thorax 1996;51:424-8.
55. Ciftçi E, Yalçinkaya F, Ince E, et al. Pulmonary involvement in childhoodonset systemic lupus erythematosus: A report of five cases. Rheumatology 2004;43:587-91.
56. de Jongste JC, Neijens HJ, Duiverman EJ, et al. Respiratory tract disease in systemic lupus erythematosus. Arch Dis Child 1986;61:478-83.
57. El-Dessoky El Shahawy E MA, Algoubashy AA, Abo-Warda MH, et al. pleuropulmonary manifestations in juvenile onset systemic lupus erythematosus: Assessment by pulmonary function tests and multidetector computed tomography. The Egyptian Rheumatologist 2011;33:163-9.
58. Gazarian M, Feldman BM, Benson LN, et al. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J Pediatr 1998;132:109-16.
59. Trapani S, Camiciottoli G, Ermini M, et al. Pulmonary involvement in juvenile systemic lupus erythematosus: A study on lung function in patients asymptomatic for respiratory disease. Lupus 1998;7:545-50.
60. Beresford MW, Cleary AG, Sills JA, et al. Cardio-pulmonary involvement in juvenile systemic lupus erythematosus. Lupus 2005;14:152-8.
61. Parodi A, Davi S, Pringe AB, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirty-eight patients. Arthritis Rheum 2009;60:3388-99.
62. Bennett TD, Fluchel M, Hersh AO, et al. Macrophage activation syndrome in children with systemic lupus erythematosus and children with juvenile idiopathic arthritis. Arthritis Rheum 2012;64:4135-42.
63. Assari R, Ziaee V, Mirmohammadsadeghi A, et al. Dynamic changes, Cut-Off Points, sensitivity, and specificity of Laboratory Data to differentiate macrophage activation syndrome from active disease. Dis Markers 2015;2015:1-8.
64. Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008;50:1227-35.
65. Mina R, Klein-Gitelman MS, Nelson S, et al. Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Ann Rheum Dis 2014;73:401-6.
66. Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2012;64:683-93.
67. Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2011;63:1213-23.
68. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR standing Committee for International clinical studies including therapeutics. Ann Rheum Dis 2008;67:195-205.
69. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against Rheumatism and european renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:1771-82.
70. Mosca M, Tani C, Aringer M, et al. European League against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010;69:1269-74.
71. Gutiérrez-Suárez R, Ruperto N, Gastaldi R, et al. A proposal for a pediatric version of the systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index based on the analysis of 1, 015 patients with juvenileonset systemic lupus erythematosus. Arthritis Rheum 2006;54:2989-96.
72. Rygg M, Pistorio A, Ravelli A, et al. A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Ann Rheum Dis 2012;71:511-7.
73. Brunner HI, Higgins GC, Klein-Gitelman MS, et al. Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2010;62:950-9.
74. Brunner HI, Silverman ED, Bombardier C, et al. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003;49:335-41.
75. Lattanzi B, Consolaro A, Solari N, et al. Measures of disease activity and damage in pediatric systemic lupus erythematosus: british Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic lupus activity measure (SLAM), Systemic lupus Erythematosus Disease Activity Index (SLEDAI), Physicians Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care Res 2011;63(Suppl 11):112-7.
76. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
77. Marks SD, Pilkington C, Woo P, et al. The use of the British Isles Lupus Assessment Group (BILAG) index as a Valid tool in assessing disease activity in childhood-onset Systemic lupus erythematosus. Rheumatology 2004;43:1186-9.
78. Al Mayouf SM AHA. Ocular manifestations of SLE in children. Saudi Med J 2003;24:964-6.
79. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-7.
80. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118:415-22.
81. ACo R. Position statement: screening for Hydroxychloroquine Retinopathy, 2011.
82. Stege H, Budde MA, Grether-Beck S, et al. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 2000;16:256-9.
83. Tucker LB, Cabral DA. Transition of the adolescent patient with rheumatic disease: issues to consider. Rheum Dis Clin North Am 2007;33:661-72.
84. Lawson EF, Hersh AO, Applebaum MA, et al. Self-management skills in adolescents with chronic rheumatic disease: A cross-sectional survey. Pediatr Rheumatol Online J 2011;9:35.
85. Hersh AO, Pang S, Curran ML, et al. The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J 2009;7:13.
86. Falcini F, Nacci F. Systemic lupus erythematosus in the young: The importance of a transition clinic. Lupus 2007;16:613-7.
87. Felsenstein S, Reiff AO, Ramanathan A. Transition of Care and Health-Related Outcomes in Pediatric-Onset systemic lupus erythematosus. Arthritis Care Res 2015;67:1521-8.
88. Foster HE, Minden K, Clemente D, et al. EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Ann Rheum Dis 2016;76.
89. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010;69:20-8.
90. Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993;28(5 Pt 1):764-70.
91. Uribe AG, Alarcón GS, Sanchez ML, et al. Systemic lupus erythematosus in three ethnic groups. XVIII. factors predictive of poor compliance with study visits. Arthritis Rheum 2004;51:258-63.
92. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000;9:601-6.
93. Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008;14:195-201.
94. M. R. Adherence to Pediatric Medical Regimens. Handbook of Child Psychology and developmental science. 7 ed. New York NY: John Wiley & Sons Inc, 2010.
95. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
96. Polido-Pereira J, Ferreira D, Rodrigues AM, et al. Rituximab use in pediatric autoimmune diseases: four case reports. Ann N Y Acad Sci 2009;1173:712-20.
97. Podolskaya A, Stadermann M, Pilkington C, et al. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child 2008;93:401-6.
98. Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008;23:413-9.
99. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-74.
100. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015;24:10-17.
101. Parikh S, Swaiman KF, Kim Y. Neurologic characteristics of childhood lupus erythematosus. Pediatr Neurol 1995;13:198-201.
102. Sibbitt WL, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536-42.
103. Turkel SB, Miller JH, Reiff A. Case series: neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J Am Acad Child Adolesc Psychiatry 2001;40:482-5.
104. Yu HH, Lee JH, Wang LC, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: A 20-year study. Lupus 2006;15:651-7.
105. Lim LS, Lefebvre A, Benseler S, et al. Psychiatric illness of systemic lupus erythematosus in childhood: spectrum of clinically important manifestations. J Rheumatol 2013;40:506-12.
106. Loh WF, Hussain IM, Soffiah A, et al. Neurological manifestations of children with systemic lupus erythematosus. Med J Malaysia 2000;55:459-63.
107. Singh S, Gupta MK, Ahluwalia J, et al. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. Rheumatol Int 2009;29:1455-61.
108. Brunner HI, Jones OY, Lovell DJ, et al. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage. Lupus 2003;12:600-6.
109. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
110. Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 2008;59:206-13.
111. dos Santos MC, Okuda EM, Ronchezel MV, et al. Verbal ability impairment in juvenile systemic lupus erythematosus. Rev Bras Reumatol 2010;50:362-74.
112. Mortilla M, Ermini M, Nistri M, et al. Brain study using magnetic resonance imaging and proton MR spectroscopy in pediatric onset systemic lupus erythematosus. Clin Exp Rheumatol 2003;21:129-35.
113. Prismich G, Hilário MO, Len CA, et al. Use of single photon emission computed tomography and magnetic resonance to evaluate central nervous system involvement in patients with juvenile systemic lupus erythematosus. Braz J Med Biol Res 2002;35:805-10.
114. Reiff A, Miller J, Shaham B, et al. Childhood central nervous system lupus; longitudinal assessment using single photon emission computed tomography. J Rheumatol 1997;24:2461-5.
115. Russo R, Gilday D, Laxer RM, et al. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998;25:576-82.
116. Szer IS, Miller JH, Rawlings D, et al. Cerebral perfusion abnormalities in children with central nervous system manifestations of lupus detected by single photon emission computed tomography. J Rheumatol 1993;20:2143-8.
117. Dong J, Li H, Wang JB, et al. Predictors for neuropsychiatric development in chinese adolescents with systemic lupus erythematosus. Rheumatol Int 2012;32:2681-6.
118. Falcini F, De Cristofaro MT, Ermini M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: A prospective SPECT study. single photon emission computed tomography. J Rheumatol 1998;25:583-8.
119. Mostafa GA, Ibrahim DH, Shehab AA, et al. The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus. J Neuroimmunol 2010;227(1-2):195-201.
120. Mostafa GA, Nazif HK, El-Shahawi HH, et al. Antineuronal antibodies and electroneurophysiological studies in pediatric patients with neuropsychiatric systemic lupus erythematosus. Pediatr Allergy Immunol 2009;20:192-9.
121. Papero PH, Bluestein HG, White P, et al. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol 1990;8:417-24.
122. Press J, Palayew K, Laxer RM, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996;39:671-6.
123. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69:2074-82.
124. Al-Obaidi M, Saunders D, Brown S, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2016;35:2449-56.
125. Gulati G, Jones JT, Lee G, et al. Altered Blood-Brain Barrier Permeability in Patients with systemic lupus erythematosus: A novel Imaging Approach. Arthritis Care Res 2017;69:299-305.
126. Brunner HI, Klein-Gitelman MS, Zelko F, et al. Validation of the Pediatric Automated Neuropsychological Assessment Metrics in childhood-onset systemic lupus erythematosus. Arthritis Care Res 2013;65:372-81.
127. Vega-Fernandez P, Vanderburgh White S, Zelko F, et al. Cognitive Performance scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset systemic lupus erythematosus. Arthritis Care Res 2015;67:1119-27.